Contents

03 July 2019
Vol 11, Issue 499

About The Cover

Cover image expansion

ONLINE COVER Inviting T Cells In. Pancreatic ductal adenocarcinoma is typically resistant to immunotherapy, in part because myeloid cells in the tumor prevent T cells (brown) from contacting and eliminating tumor cells (magenta). To overcome this obstacle, Panni et al. tested a small molecule agonist of CD11b, an integrin that is widely expressed on myeloid cells. The drug modified myeloid cell phenotypes and recruitment, which in turn enhanced T cell responses in implanted or genetically engineered murine pancreatic tumor models. Combining the CD11b agonist with treatments such as chemotherapy or checkpoint blockade led to tumor regression and survival in these models. [CREDIT: SAMARTH HEGDE AND DAVID DENARDO/WASHINGTON UNIVERSITY SCHOOL OF MEDICINE, ST. LOUIS]